→ Having submitted its FDA application to market its peanut allergy drug in December — in effect leapfrogging rival DBV Technologies $DBVT — Aimmune Therapeutics $AIMT has entered into a $170 million loan agreement with investment firm KKR.
*sigh* When will biotech's ever learn? Don't issue debt unless you are already profitable. Things can go wrong. $SGYP is a great recent example of this, an FDA approved product that is selling (though less than expected) but they're still going bankrupt because of debt. $AIMT https://t.co/lO3glhFa1x
— Maxim Jacobs, CFA (@MaxJacobsEdison) January 4, 2019
→ Germany’s Boehringer Ingelheim has picked up rights to a second RNAi program from Dicerna. the pact is centered in finding new drugs for NASH.
→ Autoimmune disease drug developer Cabaletta Bio has closed a $50 million Series B round of financing, with participation from various investors including Deerfield. The company has raised a total of $88 million since May 2018.
→ Seattle-based Immusoft has raised $20 million to pay for a Phase I/II study of its therapy for Mucopolysaccharidosis type I. Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners, and Mesa Verde Venture Partners contributed cash.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription